IBDEI0W3 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32284,1,4,0)
 ;;=4^I49.9
 ;;^UTILITY(U,$J,358.3,32284,2)
 ;;=^5007237
 ;;^UTILITY(U,$J,358.3,32285,0)
 ;;=R00.1^^119^1563^1
 ;;^UTILITY(U,$J,358.3,32285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32285,1,3,0)
 ;;=3^Bradycardia,Unspec
 ;;^UTILITY(U,$J,358.3,32285,1,4,0)
 ;;=4^R00.1
 ;;^UTILITY(U,$J,358.3,32285,2)
 ;;=^5019164
 ;;^UTILITY(U,$J,358.3,32286,0)
 ;;=I34.1^^119^1563^14
 ;;^UTILITY(U,$J,358.3,32286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32286,1,3,0)
 ;;=3^Nonrheumatic Mitral Valve Prolapse
 ;;^UTILITY(U,$J,358.3,32286,1,4,0)
 ;;=4^I34.1
 ;;^UTILITY(U,$J,358.3,32286,2)
 ;;=^5007170
 ;;^UTILITY(U,$J,358.3,32287,0)
 ;;=D68.4^^119^1564^1
 ;;^UTILITY(U,$J,358.3,32287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32287,1,3,0)
 ;;=3^Acquired Coagulation Factor Deficiency
 ;;^UTILITY(U,$J,358.3,32287,1,4,0)
 ;;=4^D68.4
 ;;^UTILITY(U,$J,358.3,32287,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,32288,0)
 ;;=D59.9^^119^1564^2
 ;;^UTILITY(U,$J,358.3,32288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32288,1,3,0)
 ;;=3^Acquired Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,32288,1,4,0)
 ;;=4^D59.9
 ;;^UTILITY(U,$J,358.3,32288,2)
 ;;=^5002330
 ;;^UTILITY(U,$J,358.3,32289,0)
 ;;=C91.00^^119^1564^5
 ;;^UTILITY(U,$J,358.3,32289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32289,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32289,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,32289,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,32290,0)
 ;;=C91.01^^119^1564^4
 ;;^UTILITY(U,$J,358.3,32290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32290,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32290,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,32290,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,32291,0)
 ;;=C92.01^^119^1564^7
 ;;^UTILITY(U,$J,358.3,32291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32291,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32291,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,32291,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,32292,0)
 ;;=C92.00^^119^1564^8
 ;;^UTILITY(U,$J,358.3,32292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32292,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32292,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,32292,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,32293,0)
 ;;=C92.61^^119^1564^9
 ;;^UTILITY(U,$J,358.3,32293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32293,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
 ;;^UTILITY(U,$J,358.3,32293,1,4,0)
 ;;=4^C92.61
 ;;^UTILITY(U,$J,358.3,32293,2)
 ;;=^5001808
 ;;^UTILITY(U,$J,358.3,32294,0)
 ;;=C92.60^^119^1564^10
 ;;^UTILITY(U,$J,358.3,32294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32294,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,32294,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,32294,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,32295,0)
 ;;=C92.A1^^119^1564^11
 ;;^UTILITY(U,$J,358.3,32295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32295,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,32295,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,32295,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,32296,0)
 ;;=C92.A0^^119^1564^12
 ;;^UTILITY(U,$J,358.3,32296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32296,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32296,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,32296,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,32297,0)
 ;;=C92.51^^119^1564^13
 ;;^UTILITY(U,$J,358.3,32297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32297,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32297,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,32297,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,32298,0)
 ;;=C92.50^^119^1564^14
 ;;^UTILITY(U,$J,358.3,32298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32298,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32298,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,32298,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,32299,0)
 ;;=C94.40^^119^1564^17
 ;;^UTILITY(U,$J,358.3,32299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32299,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,32299,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,32299,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,32300,0)
 ;;=C94.42^^119^1564^15
 ;;^UTILITY(U,$J,358.3,32300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32300,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,32300,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,32300,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,32301,0)
 ;;=C94.41^^119^1564^16
 ;;^UTILITY(U,$J,358.3,32301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32301,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,32301,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,32301,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,32302,0)
 ;;=D62.^^119^1564^18
 ;;^UTILITY(U,$J,358.3,32302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32302,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,32302,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,32302,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,32303,0)
 ;;=C92.41^^119^1564^19
 ;;^UTILITY(U,$J,358.3,32303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32303,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32303,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,32303,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,32304,0)
 ;;=C92.40^^119^1564^20
 ;;^UTILITY(U,$J,358.3,32304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32304,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32304,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,32304,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,32305,0)
 ;;=D56.0^^119^1564^21
 ;;^UTILITY(U,$J,358.3,32305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32305,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,32305,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,32305,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,32306,0)
 ;;=D63.1^^119^1564^23
 ;;^UTILITY(U,$J,358.3,32306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32306,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,32306,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,32306,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,32307,0)
 ;;=D63.0^^119^1564^24
 ;;^UTILITY(U,$J,358.3,32307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32307,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,32307,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,32307,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,32308,0)
 ;;=D63.8^^119^1564^22
 ;;^UTILITY(U,$J,358.3,32308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32308,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,32308,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,32308,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,32309,0)
 ;;=C22.3^^119^1564^26
 ;;^UTILITY(U,$J,358.3,32309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32309,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,32309,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,32309,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,32310,0)
 ;;=D61.9^^119^1564^27
 ;;^UTILITY(U,$J,358.3,32310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32310,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,32310,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,32310,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,32311,0)
 ;;=D56.1^^119^1564^29
 ;;^UTILITY(U,$J,358.3,32311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32311,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,32311,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,32311,2)
 ;;=^340495
